Total Payments
$8,513
2024 Payments
$3,699
Companies
52
Transactions
345
Medicare Patients
1,399
Medicare Billing
$194,353
Payment Breakdown by Category
Food & Beverage$6,444 (75.7%)
Other$1,729 (20.3%)
Education$339.98 (4.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,444 | 323 | 75.7% |
| Long term medical supply or device loan | $1,729 | 18 | 20.3% |
| Education | $339.98 | 4 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,356 | 48 | $0 (2024) |
| Janssen Biotech, Inc. | $570.72 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $558.17 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $413.02 | 22 | $0 (2024) |
| Celgene Corporation | $410.57 | 20 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $403.22 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $380.62 | 18 | $0 (2024) |
| Amgen Inc. | $326.05 | 25 | $0 (2023) |
| ABBVIE INC. | $216.18 | 10 | $0 (2024) |
| GENZYME CORPORATION | $214.46 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,699 | 127 | Novartis Pharmaceuticals Corporation ($1,409) |
| 2023 | $1,765 | 73 | Celgene Corporation ($175.17) |
| 2022 | $606.52 | 32 | Amgen Inc. ($65.46) |
| 2021 | $2,442 | 113 | Novartis Pharmaceuticals Corporation ($752.08) |
All Payment Transactions
345 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: Oncology | ||||||
| 12/11/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Oncology | ||||||
| 11/26/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI, PEMAZYRE | Food and Beverage | Cash or cash equivalent | $20.83 | General |
| Category: Hematology/Oncology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Hematology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $29.37 | General |
| Category: Hematology | ||||||
| 10/30/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Oncology | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Oncology | ||||||
| 10/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 459 | 823 | $75,125 | $42,004 |
| 2022 | 4 | 128 | 151 | $17,221 | $4,535 |
| 2021 | 2 | 60 | 65 | $20,566 | $5,606 |
| 2020 | 19 | 752 | 34,850 | $685,802 | $142,207 |
Total Patients
1,399
Total Services
35,889
Medicare Billing
$194,353
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 214 | 435 | $33,081 | $18,921 | 57.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 237 | $26,543 | $15,376 | 57.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $3,786 | $2,160 | 57.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 41 | 41 | $3,820 | $2,148 | 56.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 17 | $3,177 | $1,610 | 50.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 30 | $1,194 | $681.80 | 57.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 19 | 27 | $2,554 | $592.25 | 23.2% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 11 | 11 | $970.09 | $515.60 | 53.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 36 | $3,967 | $2,398 | 60.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 67 | 86 | $11,509 | $837.25 | 7.3% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 17 | 18 | $923.58 | $798.14 | 86.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $821.92 | $501.82 | 61.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 52 | $11,648 | $4,348 | 37.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 12 | 13 | $8,918 | $1,258 | 14.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 18 | 2,580 | $148,200 | $39,886 | 26.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 250 | 548 | $122,752 | $35,997 | 29.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2020 | 22 | 29,250 | $117,000 | $24,261 | 20.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 35 | 130 | $89,180 | $11,958 | 13.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 126 | 197 | $29,156 | $9,301 | 31.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 32 | 36 | $10,836 | $3,381 | 31.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $11,232 | $2,933 | 26.1% |
| 38222 | Bone marrow biopsy and aspiration | Office | 2020 | 21 | 24 | $12,552 | $2,782 | 22.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 19 | 53 | $16,112 | $2,435 | 15.1% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 35 | 209 | $21,945 | $2,256 | 10.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2020 | 15 | 560 | $68,320 | $2,043 | 3.0% |
About Sarah Rowe, MSN, FNP-BC, OCN
Sarah Rowe, MSN, FNP-BC, OCN is a Family healthcare provider based in Panama City, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2018. The National Provider Identifier (NPI) number assigned to this provider is 1427549765.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sarah Rowe, MSN, FNP-BC, OCN has received a total of $8,513 in payments from pharmaceutical and medical device companies, with $3,699 received in 2024. These payments were reported across 345 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($6,444).
As a Medicare-enrolled provider, Rowe has provided services to 1,399 Medicare beneficiaries, totaling 35,889 services with total Medicare billing of $194,353. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Panama City, FL
- Active Since 05/22/2018
- Last Updated 10/04/2024
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1427549765
Products in Payments
- KISQALI (Drug) $1,905
- LIBTAYO (Biological) $419.57
- KEYTRUDA (Biological) $363.72
- OPDIVO (Biological) $325.92
- DARZALEX (Biological) $275.23
- IMBRUVICA (Drug) $262.74
- REBLOZYL (Biological) $247.64
- Lenvima (Drug) $176.87
- IMFINZI (Biological) $162.57
- BRUKINSA (Drug) $138.83
- CABOMETYX (Drug) $136.67
- Kyprolis (Drug) $133.87
- MONJUVI (Drug) $126.32
- Xospata (Drug) $113.10
- MEKINIST (Drug) $112.41
- SARCLISA (Biological) $111.59
- SCEMBLIX (Drug) $110.88
- CALQUENCE (Drug) $109.98
- Orserdu (Drug) $109.21
- LYNPARZA (Drug) $105.07
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Panama City
Jennifer Reeves, Aprn, APRN
Family — Payments: $12,092
Family $12,092
Andrew Rising, Aprn, APRN
Family — Payments: $9,388
Family $9,388
Dr. Tracy Adams, Dnp, Arnp, Fnp-C, DNP, ARNP, FNP-C
Family — Payments: $6,642
Family $6,642
Ashli Brooks, Fnp-Bc, FNP-BC
Family — Payments: $6,201
Family $6,201
Dr. Sarah Stokes, Dnp, Arnp-Bc, DNP, ARNP-BC
Family — Payments: $5,024
Family $5,024
Mary Carmon, Np, NP
Family — Payments: $4,682
Family $4,682